Alvogen Inc, the US-based generic pharmaceutical company, today announces that it has added to its Global Business Development and R&D teams. These appointments will further strengthen Alvogen’s capability to
New Jersey, April 15th, 2010 - Alvogen Inc. ("Alvogen"), the US-based generic pharmaceutical company, today announces that it has added to its Global Business Development and R&D teams. These appointments will further strengthen Alvogen’s capability to built a strategically selected portfolio of products for the US and world markets and pursue first-to-file opportunities.
The new leaders are:
Dr. Georg Ingramwill lead Alvogen’s Global Business Development as Executive Vice President. Ingram brings 16 years of experience in the generic industry. His focus will be on exploring strategic opportunities to expand Alvogen’s international product portfolio and to build a network of partners throughout the world for in-licensing of products in all therapeutic areas, including biosimilars. Ingram was previously the Vice President of Global Portfolio Management at Actavis Group, after spending six years with Sandoz GmbH in Marketing, and later Head of Global Business Development. Ingram studied Chemistry and graduated with a M.Sc. and a PhD. degree from the University of Innsbruck.
Dale Martin will lead Alvogen´s first-to-file product development team that will pursue opportunities for the US market, as Vice President of Strategic Development. Prior to joining Alvogen, Martin acquired over 30 years of experience, holding a variety of positions in the generic industry. He began his career with Mylan Pharmaceuticals in 1977 and later worked with Abrika Pharmaceuticals (subsidiary of Actavis Group) as VP of Corporate Development, later promoted to a Managing Director position, until he decided to join Alvogen. Martin graduated with a bachelor’s degree and a M.B.A. from West Virginia University in 1974 and 1976. Jasmine Shahjoins Alvogen as Vice President of Research, Development and Regulatory Affairs. He will be responsible for developing Alvogen’s product portfolio for the US market through product development partnerships and collaborations worldwide. Shah joins Alvogen after spending four years with Actavis Group as VP of Regulatory and Medical Affairs in the U.S. Previously he served in a VP capacity for Actavis subsidiary in the US for a number of years. Shah has been the driving force behind over 100 ANDA development and submission projects. A licensed pharmacist by profession in the U.S., Shah holds an undergraduate degree in Pharmacy from University of Poona, India and a Masters degree in Industrial Pharmacy from Long Island University, US.
"Our expanded team will accelerate our R&D and business development activities and support our global growth strategy. They all bring tremendous experience from world class organizations that will supplement our passion and energy at Alvogen", said Robert Wessman, Executive Chairman of Alvogen.